BioCryst Pharmaceuticals | BCRX - Betriebsaufwand

Aktienkurs
9.78
Täglich Wechseln
0.08 0.82%
Monatlich
28.52%
Jährlich
21.49%
Q1 Prognose
9.41




Betriebsaufwand Veränderung Datum
Alnylam Pharmaceuticals USD 965.32M 84.27M 2025-12
BioCryst Pharmaceuticals USD 146.17M 534.06M 2025-12
Chugai Pharma JPY 177.3B 604M 2025-12
Daiichi Sankyo JPY 468.57B 15.34B 2025-12
DBV Technologies USD 37.05M 4.06M 2025-09
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
GlaxoSmithKline GBP 7.18B 1.42B 2025-12
Glaxosmithkline GBP 9.17B 1.4B 2025-12
Incyte USD 1.12B 3.53B 2025-12
Ionis Pharmaceuticals USD 418M 101.1M 2025-12
Karyopharm Therapeutics USD 61.82M 3.24M 2024-12
Neurocrine Biosciences USD 577.6M 22M 2025-12
Novavax USD 126.2M 23.62M 2025-12
PTC Therapeutics USD 246.3M 38.78M 2025-12
Regeneron Pharmaceuticals USD 2.99B 27.97B 2025-12
Roche Holding CHF 21.01B 10.84B 2025-12
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12
Vertex Pharmaceuticals USD 1.93B 89.1M 2025-12